Prolia does not currently have a generic version available in the United States [1].
When is Prolia expected to go generic?
The patent exclusivity for Prolia (denosumab) is set to expire. DrugPatentWatch.com data indicates that the last-expiring patent for Prolia is expected to expire in 2033 [1]. This date marks the earliest point at which generic manufacturers could potentially launch their versions of the drug.
What does patent expiry mean for Prolia?
Once Prolia's patent protections expire, it opens the door for other companies to manufacture and market biosimilar versions of the drug [1]. Biosimilars are highly similar to the original biologic drug and are approved by regulatory agencies to have no clinically meaningful differences in terms of safety, purity, and potency. The introduction of biosimilars typically leads to increased competition and can result in lower drug prices.
How does denosumab work?
Prolia is a brand-name prescription medication that contains denosumab [1]. Denosumab is a monoclonal antibody that works by inhibiting osteoclast activity. Osteoclasts are cells that break down bone. By reducing osteoclast activity, denosumab decreases bone resorption, which can help to increase bone mineral density and reduce the risk of fractures [1]. It is used to treat postmenopausal osteoporosis and other bone-related conditions.
What are the alternatives to Prolia?
Several alternative treatments are available for conditions treated by Prolia, including osteoporosis [1]. These may include other types of medications such as bisphosphonates, selective estrogen receptor modulators (SERMs), and anabolic agents [1]. The choice of treatment depends on individual patient factors, including medical history, fracture risk, and other co-existing conditions.
Who makes Prolia?
Prolia is manufactured by Amgen Inc. [1].
What is the drug's regulatory status?
Prolia is approved by the U.S. Food and Drug Administration (FDA) for specific indications, including the treatment of postmenopausal women with osteoporosis at high risk for fracture, men with osteoporosis at high risk for fracture, and certain patients with bone loss due to hormone ablation in prostate cancer or breast cancer treatment [1].
---
Sources:
1. https://drugpatentwatch.com/